Health
FDA Probes Death of Boy in Brazil on Sarepta’s Elevidys
The Sarepta Therapeutics headquarters in Cambridge, Mass.
Photographer: Cassandra Klos/BloombergUS regulators are investigating the death of an 8-year-old boy in Brazil who received Sarepta Therapeutics Inc.’s Elevidys.
The death occurred on June 7, according to a statement from the US Food and Drug Administration, which did not specify where the boy lived.